SunTrust Banks Inc. reaffirmed their buy rating on shares of Tesaro Inc. (NASDAQ:TSRO) in a research note released on Wednesday morning. They currently have a $91.60 target price on the biopharmaceutical company’s stock.

Other analysts have also issued reports about the stock. Robert W. Baird began coverage on shares of Tesaro in a research report on Monday, July 18th. They issued an outperform rating and a $105.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of Tesaro in a research report on Friday, August 12th. They issued an outperform rating and a $122.00 price objective on the stock. FBR & Co increased their price objective on shares of Tesaro from $65.00 to $93.00 and gave the stock an outperform rating in a research report on Wednesday, June 29th. Mizuho reissued an outperform rating and issued a $67.00 price objective on shares of Tesaro in a research report on Thursday, June 30th. Finally, Wedbush reissued a buy rating on shares of Tesaro in a research report on Friday, August 5th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of Buy and an average target price of $94.40.

Shares of Tesaro (NASDAQ:TSRO) opened at 104.11 on Wednesday. The company’s market capitalization is $5.35 billion. The stock has a 50 day moving average price of $91.68 and a 200-day moving average price of $61.56. Tesaro has a 12 month low of $29.51 and a 12 month high of $104.48.

Tesaro (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The company had revenue of $36.60 million for the quarter, compared to analyst estimates of $4.98 million. During the same period in the prior year, the company posted ($1.51) EPS. Analysts forecast that Tesaro will post ($7.33) EPS for the current year.

In other Tesaro news, VP Jeffrey H. Hanke sold 12,500 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total value of $929,375.00. Following the completion of the sale, the vice president now directly owns 12,500 shares in the company, valued at $929,375. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Edward C. English sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 8th. The shares were sold at an average price of $88.54, for a total transaction of $619,780.00. Following the completion of the sale, the vice president now owns 3,500 shares of the company’s stock, valued at $309,890. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in TSRO. Passport Capital LLC purchased a new stake in shares of Tesaro during the second quarter valued at $61,720,000. FMR LLC increased its stake in shares of Tesaro by 9.6% in the second quarter. FMR LLC now owns 6,097,449 shares of the biopharmaceutical company’s stock valued at $512,490,000 after buying an additional 531,892 shares during the period. Pictet Asset Management Ltd. increased its stake in shares of Tesaro by 661.3% in the second quarter. Pictet Asset Management Ltd. now owns 418,730 shares of the biopharmaceutical company’s stock valued at $19,387,000 after buying an additional 363,730 shares during the period. Emerald Acquisition Ltd. purchased a new stake in shares of Tesaro during the second quarter valued at $23,685,000. Finally, Vanguard Group Inc. increased its stake in shares of Tesaro by 11.0% in the second quarter. Vanguard Group Inc. now owns 2,216,739 shares of the biopharmaceutical company’s stock valued at $186,317,000 after buying an additional 219,902 shares during the period. Institutional investors own 88.87% of the company’s stock.

About Tesaro

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

5 Day Chart for NASDAQ:TSRO

Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.